Medivir Ab
HUDDINGE, Sweden, May 20, 2011 - Medivir AB (OMX: MVIR), the emerging research-based specialty
pharmaceutical company focused on infectious diseases, today announced
results from the ASPIRE phase 2b study that evaluates the addition of once
daily TMC435 to pegylated interferon and ribavirin in patients with genotype
1 chronic hepatitis C whose prior treatment with pegylated-interferon
(PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed,
had a partial response or had a null response.